Taysha gene therapies reports first quarter 2023 financial results and provides corporate update

Screening completed and dosing scheduled for first potential subject in the phase 1/2 reveal trial in rett syndrome; dosing of first adult patient with tsha-102 expected in q2 2023; initial available phase 1/2 clinical data, primarily on safety, expected in q2 2023
TSHA Ratings Summary
TSHA Quant Ranking